Recruiting
Phase 2

Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Sponsor:

National Cancer Institute (NCI)

Code:

NCT05600894

Conditions

Chronic Myelomonocytic Leukemia

Myelodysplastic Syndrome

Myelodysplastic Syndrome With Excess Blasts

Myelodysplastic/Myeloproliferative Neoplasm

Myeloproliferative Neoplasm

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Bone Marrow Aspiration

Bone Marrow Biopsy

Decitabine and Cedazuridine

Venetoclax

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information